Driven by a consolidation of offerings, the number of Part D prescription drug plans will decrease by 14% in 2015. While monthly premiums will decrease overall by 2%, there will be large premium variations.
Driven by a consolidation of offerings, the number of Part D prescription drug plans will decrease by 14% in 2015, according to Avalere Health’s analysis of CMS’ filings for 2015.
Plan sponsors will rely on more highly managed plan products. The number of health maintenance organization plans will increase 1.5%, while the number of preferred provider organizations will decrease by nearly 9% from 2014 to 2015.
Top plan sponsors like Aetna, Cigna, CVS, and UnitedHealth are driving the prescription drug plan reduction by consolidating their offerings. As a result, the average monthly premiums for these drug plans will decrease by 2% from $39.88 in 2014 to $38.95 as a large number of beneficiaries are shifted into lower-cost plans, according to Avalere’s calculations.
Avalere warns about large premium variations. Aetna’s new Medicare Rx Saver plan reduces premiums by more than 30%, but WellCare’s Classic plan is increasing premiums by more than 50%. However, overall, half of the top 10 prescription drug plans will have average premiums lower than $30.
“When seniors choose a prescription drug plan for 2015, they should carefully look at their options to select the plan that best meets their health and financial needs,” Christine Harhaj, senior manager at Avalere Health, said in a statement. “While beneficiaries will welcome lower premiums, they will need to look at other facets of benefit design including how their medications are covered, cost sharing responsibilities, and total out-of-pocket spending.”
In 2015, 42% of drug plans will have $0 deductibles, a decline from 47% in 2014. Additionally, roughly three-quarters of plans will not cover drugs in the Part D coverage gap next year.
The number of plans participating in Medicare Advantage will also decline 3% to 2,450 in 2015 from 2,527 in 2014. The regions that will see the most sizeable plan withdrawals are high-population density areas in the Southeast and the Mid-Atlantic.
“To succeed in the market today, Medicare health plans need to be efficient, reasonably priced, and focused on quality metrics,” Dan Mendelson, chief executive officer of Avalere Health, said in a statement. “There will inevitably be some plans that can’t survive in this demanding environment, and others that enter precisely because their operations are prepared to meet the challenge of public programs.”
The Supreme Court seems likely to reject a challenge to the abortion pill mifepristone; the FDA is inspecting far fewer pharmaceutical companies conducting clinical research; AstraZeneca has sued to block an Arkansas law that it said would unlawfully expand the 340B program to include for profit-pharmacy chains.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Covered Preventive Services at Risk: V-BID Summit Breaks Down the Braidwood v Becerra Case
March 20th 2024For more than a decade, certain high-value preventive care services have been covered at no cost to patients under the Affordable Care Act, but a current legal challenge has the coverage at risk.
Read More
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Most private health insurers have yet to publish criteria for when they will cover postpartum depression drug, zuranolone; state lawmakers are increasingly opposing health care mergers that they believe do not serve the public interest; Medicaid extensions made in 2021 led to a 40% decline in postpartum lack of insurance.
Read More
President Biden will preview his plan to more than double the size of Medicare’s new drug price negotiation program in the upcoming State of the Union address; Mexicans and Central Americans were most affected by the pandemic in terms of all-cause mortality; two Alabama fertility clinics said they expect to resume in vitro fertilization (IVF) services after a bill was passed to protect doctors.
Read More